H 002
Alternative Names: H-002Latest Information Update: 04 Sep 2022
At a glance
- Originator RedCloud Bio
 - Class Antineoplastics; Small molecules
 - Mechanism of Action Epidermal growth factor receptor antagonists
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Phase I/II Non-small cell lung cancer
 
Most Recent Events
- 29 Aug 2022 Phase-I/II clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in China (PO)
 - 29 Aug 2022 Phase-I/II clinical trials in Non-small cell lung cancer (Inoperable/Unresectable, Late-stage disease, Metastatic disease, Second-line therapy or greater, Monotherapy) in USA (PO) (NCT05519293)
 - 29 Aug 2022 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer released by RedCloud Bio